Program Coordinator:Laura Kasman, Ph.D.kasmanL@musc.edu

M&I program currentlyM&I program currently 17 Ph.D. students 4 MD/Ph.D. students 1 DMD/Ph.D. student 2 Masters students 15 Departmental faculty 40 Total Program faculty

Program RequirementsProgram Requirements 6 credits in advanced M&I courses in 2nd

year

Written qualifying exam, summer after 2nd year

Thesis proposal defense, usually sometime in 3rd year for admission to candidacy

12 advanced credits total, not including M&I Seminar

M&I Advanced course offeringsM&I Advanced course offeringsOffered Every Year

FALL SPRING

MBIM 613G Infection MBIM 623G Dental MicrobiologyMBIM 614G Immunity MBIM 702 Oral Immunobiology

MBIM 905 Translational Genomics M&I Selective

MBIM 770 Seminar MBIM 770 Seminar

Offered academic cycles beginning in odd years: 2007, 2009, 2011...

MBIM 742 Advanced Microbiology MBIM731 Advanced Topics in Immunology

Offered academic cycles beginning in even years: 2008, 2010, 2012...

MBIM 725 Virology MBIM 772 Environmental Micro

MBIM 775 Special Topics MBIM 775A Bioentrepreneurship

MBIM 779 Immunogenetics

Departmental vs. Program FacultyDepartmental vs. Program Faculty

Department Faculty have M&I as their home department

M&I Program Faculty can be faculty members from any MUSC department that have research interests related to microbiology or immunology

Faculty can be affiliated with more than one graduate program

M&I Department Faculty InterestsM&I Department Faculty Interests

bacteriology

virology

immunology

gene therapy

BacteriologistsBacteriologists

Michael Schmidt Hal May Ed Balish

VirologistsVirologists

Natalie Sutkowski John Y. Dong Laura Kasman

ImmunologistsImmunologists

Janardan Stephen Gabriel Aziz Carl Pandey Tomlinson Virella Haque Atkinson

Also Natalie Sutkowski

Tumor Immunologists & Gene TherapyTumor Immunologists & Gene Therapy

James Norris Christina Xiang Liu Semyon Voelkel-Johnson Rubinchik

Also Stephen Tomlinson & John Dong

Program FacultyProgram FacultySurgerySurgery Prabhakar Baliga Mike Nishimura Kenneth Chavin David Cole Yi Zhang

PathologyPathology Amanda LaRue

OtolaryngologyOtolaryngology Rita Young

Neurosciences/NeurologyNeurosciences/Neurology Narendra Banik Narayan Bhat James Cook William Tyor Swapan Ray

PediatricsPediatrics Inderjit Singh Isabel Virella-Lowell

Program FacultyProgram FacultyCollege of Dental MedicineCollege of Dental Medicine Robert Boackle Caroline Westwater

Radiation OncologyRadiation Oncology Sebastiano Gattoni-Celli

College of Pharmaceutical College of Pharmaceutical SciencesSciences

Craig Beeson

Cell Biology & AnatomyCell Biology & Anatomy Titus Reaves

RheumatologyRheumatology James Oates Maria Trojanowska Gary Gilkeson

BiochemistryBiochemistry Greg Warr Maurizio Del Poeta

Division of Infectious Division of Infectious DiseaseDisease

Christopher Parsons

Entrepreneurship by M&I facultyEntrepreneurship by M&I faculty

Company Faculty Technology

GenPharGenPhar Dr. Dong Adenovirus-based subunit vaccines

SphingoGeneSphingoGene Dr. Norris Ceramide-modifying

anti-cancer agents

TaligenTaligen Dr.

Tomlinson

Therapeutic complement inhibitors

MFC TechMFC Tech Dr. May Bacterial electricity generation, Microbial fuel

cells

MOUNT PLEASANT, SC (AUGUST 30, 2007) - Groundbreaking ceremony for new facility at Innovation Park, in the economic development zone of The Market at Oakland.

MOUNT PLEASANT, SC (AUGUST 30, 2007) - Groundbreaking ceremony for new facility at Innovation Park, in the economic development zone of The Market at Oakland.

GenPhar, Inc. is a biopharmaceutical company dedicated to providing vaccines that protect against infectious diseases with great socio-economic impacts worldwide.

Biodefense programs: GenPhar's vaccine platform is ideally designed for biodefense because one vaccine can prevent infection from multiple virus subtypes.

James S. Norris, PhDCo-Founder, SphingoGene, Inc.

http://www.sphingogene.comProfessor and Chairman, MUSC

norrisjs@musc.edu

SphingoGene, Inc.

NH CO

O H 12

O H

(2S, 3R, 4E) D-erythro -Ceramide

34

5

n

SphingoGene, Inc. is focused on commercialization of small molecule therapeutics that modify ceramide metabolism to overcome resistance to chemo and radiation therapy and promote apoptosis in cancer cells. Ceramide is a “tumor suppressor sphingolipid” involved in regulation of cell death. SphingoGene, Inc.’s molecules are rationally designed and proven to inhibit enzymes that create resistance to conventional cancer therapies. Our goal is to utilize these small molecules in combination with “standard of care” radiation or chemotherapy to enhance cancer cell death.

Commercial Lipidomic Services

Molecular diagnostic to predict patientResponse

Combination therapy for standard of care

Therapies in cancer patients (chemo, radiation and gene therapy

Products and Services

Controlling Inflammation to Treat Human DiseaseApplying novel technologies to create better treatmentsContact: Woodruff Emlen MDwemlen@taligentherapeutics.com

Taligen Therapeutics, Inc. is a development stage biotechnology company with novel technology to modulate and regulate activation of the complement system. Inappropriate complement activation leading to inflammation is a major contributor to a large number of human diseases.

Taligen has proof of concept data in animal models of diseases as diverse as asthma, macular degeneration, immune renal disease, inflammatory arthritis, ischemia-reperfusion injury, stroke and traumatic brain injury.

Product DevelopmentCurrently focused on the areas of asthma and age related macular degeneration.

Stephen Tomlinson, PhDProfessortomlinss@musc.edu

Dr. Hal May, Ph.D.VP, MFC Technologies LLC

http://www.mfctech.nethmay@mfctech.net Assoc. Prof. MUSCmayh@musc.edu

Microbially Generated Electricity

Increase Biofuel Production

24/7 Remote Power, Sensor Control

Control Waste, Odor and Algae

MFC Tech is focused on the development of microbial fuel cell technology (MFCs), which utilizes the ability of bacteria to generate electricity.

Patentable approaches are targeted for the enhancement of waste management and electricity generation, namely…

24/7 remote power generation such as along highways and in retention ponds

Development of specific sensors or the powering of sensors in remote locations

Enhancement of biofuel production through the application of MFC technology to cellulosic ethanol fermentation

The reduction of agricultural waste, odors and algal blooms in waste lagoons and retention ponds